New classification criteria for spondyloarthritis cover a wide spectrum of patients.
Men are more likely to stay the course of TNF inhibitor therapy.
A study sheds new light on the extra-articular manifestations of spondyloarthritis—with a focus on the heart as a high-risk target.
Are you prepared to recognize and treat anxiety, depression, and other comorbid psychiatric disorders when they arise in your patients?
This is the only fully human anti-TNF-α infused therapy approved for psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.
In this slideshow, we highlight newly released treatment recommendations for rheumatic disease patients undergoing total hip or total knee arthroplasty.
Rheumatic patients are more prone to complications post knee and hip surgery. Two physician associations have penned new treatment guidelines.
Clinical trial shows that switching from the infliximab originator to its biosimilar does not compromise safety or effectiveness of treatment.
Chronic back pain, arthritis and enthesitis are among common axSpA manifestations, but no two patients are alike. Here, we highlight key presentations.
EULAR-ASAS have updated the 2010 guidelines for axSpA emphasizing treat to target, tapering and for the first time, cost considerations.